Revelation Biosciences Inc. Announces Financial Results for the Three and Nine Months Ended September 30, 2022 and Recent Corporate Progress

Rhea-AI Summary

Revelation Biosciences Inc. (NASDAQ: REVB) reported its third quarter 2022 financial results, highlighting key corporate developments. The company completed a $5.0 million public offering and licensed innovative IP for REVTx-100 aimed at healthcare-associated infections. Notably, positive preclinical data for REVTx-300 in kidney-related conditions was announced. As of September 30, 2022, cash and cash equivalents rose to $6.2 million from $1.3 million in 2021. However, the company recorded a net loss of $1.2 million for Q3 2022, down from $3.0 million in Q3 2021, indicating improved financial performance.

Positive

• Completed a $5.0 million public offering.
• Cash and cash equivalents increased to $6.2 million from $1.3 million YoY.
• Net loss improved to $1.2 million for Q3 2022 from $3.0 million in Q3 2021.

Negative

• Net cash used for operating activities increased to $1.7 million in Q3 2022 from $2.2 million in Q3 2021.
• Total net loss for the nine months ended September 30, 2022, was $9.6 million, an increase from $8.1 million in 2021.

SAN DIEGO--(BUSINESS WIRE)-- Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a life sciences company that is focused on the development of immunologic based therapies for the prevention and treatment of disease, today reported its third quarter 2022 financial results and highlighted recent corporate progress.

Corporate Highlights

• Completed a $5.0 million public offering.
• Licensed innovative intellectual property from Vanderbilt University (US Patent 11,389,465) for REVTx-100, which is being developed for the prevention and treatment of healthcare associated infections.
• Announced positive data from a preclinical study of REVTx-300 in acute kidney injury and chronic kidney disease.
• Expected preclinical data from the PEITHO study of intranasal REVTx-200 in conjunction with a vaccine compared to vaccination alone.
• Anticipate starting the combined Phase 1a clinical study for RETx-100 and REVTx-300.

“Revelation is in a position for a great 2023, starting with more REVTx-300 preclinical efficacy data in the first half of 2023 and the initiation of our planned Phase 1a clinical study for both REVTx-100 and REVTx-300,” said James Rolke, Chief Executive Officer of Revelation. “We remain committed to the development of our PHAD based platform and deepening our pipeline.”

Results of Operations

As of September 30, 2022, Revelation had $6.2 million in cash and cash equivalents, compared to $1.3 million as of December 31, 2021. The increase in cash and cash equivalents was primarily due to net cash received from financing activities, offset primarily by cash used for operating activities. Based on current operating plans and projections, including the proceeds of the recent public offering, Revelation believes that its current cash and cash equivalents are sufficient to fund operations through June of 2023.

Revelation’s net cash used for operating activities for the three and nine months ended September 30, 2022 was $1.7 million and $10.3 million, respectively, compared to net cash used for operating activities of $2.2 million and $8.2 million, respectively, for the same periods in 2021. Revelation’s net loss for the three and nine months ended September 30, 2022 was $1.2 million and $9.6 million, or $0.06 per share and $0.57 per share, respectively, compared to a net loss of $3.0 million and $8.1 million, or $0.48 per share and $3.83 per share, for the same periods in 2021.

The increases in net cash used for operating activities and net loss in 2022 as compared to 2021 were primarily due to clinical study expenses associated with our Phase 2b viral challenge clinical study (REVTx-99a) and our Phase 1b allergen challenge study (REVTx-99b), financial advisory fees, legal fees, professional consulting service fees, and the public company directors and officers insurance policy.

About Revelation Biosciences Inc.

Revelation Biosciences, Inc. is a life sciences company focused on the development of immunologic-based therapies for the prevention and treatment of disease. Revelation has multiple product candidates in development that are based on the well-established biology of phosphorylated hexaacyl disaccharide (PHAD) and its effect on the innate immune system. REVTx-100 is being developed as a prevention and treatment of infection. REVTx-200 is being developed as an intranasal immunomodulator adjunct to be used in combination with an intramuscular vaccination for more complete immunity. REVTx-300 is being developed as a potential therapy for the treatment of acute and chronic organ disease including CKD, AKI, myocarditis, and NASH. REVTx-99b is being developed as a treatment for food allergies. REVDx-501 is being developed as a rapid diagnostic that can be used to detect IP-10 as a surrogate biomarker for any type of respiratory infection, without the need for specialized instrumentation.

For more information on Revelation, please visit www.RevBiosciences.com.

Forward-Looking Statements

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These forward-looking statements are generally identified by the words "anticipate", "believe", "expect", "estimate", "plan", "outlook", and "project" and other similar expressions. We caution investors that forward-looking statements are based on management’s expectations and are only predictions or statements of current expectations and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from those anticipated by the forward-looking statements. Revelation cautions readers not to place undue reliance on any such forward looking statements, which speak only as of the date they were made. The following factors, among others, could cause actual results to differ materially from those described in these forward-looking statements: the ability of Revelation to meet its financial and strategic goals, due to, among other things, competition; the ability of Revelation to grow and manage growth profitability and retain its key employees; the possibility that the Revelation may be adversely affected by other economic, business, and/or competitive factors; risks relating to the successful development of Revelation’s product candidates; the clinical utility of an increase in intranasal cytokine levels as a biomarker of viral infections; the ability to successfully complete planned clinical studies of its product candidates; the risk that we may not fully enroll our clinical studies or enrollment will take longer than expected; risks relating to the occurrence of adverse safety events and/or unexpected concerns that may arise from data or analysis from our clinical studies; changes in applicable laws or regulations; expected initiation of the clinical studies, the timing of clinical data; the outcome of the clinical data, including whether the results of such study is positive or whether it can be replicated; the outcome of data collected, including whether the results of such data and/or correlation can be replicated; the timing, costs, conduct and outcome of our other clinical studies; the anticipated treatment of future clinical data by the FDA, the EMA or other regulatory authorities, including whether such data will be sufficient for approval; the success of future development activities for its product candidates; potential indications for which product candidates may be developed; the potential impact that COVID-19 may have on Revelation’s suppliers, vendors, regulatory agencies, employees and the global economy as a whole; the ability of Revelation to maintain the listing of its securities on NASDAQ; investor sentiment relating to SPAC related going public transactions; the expected duration over which Revelation’s balances will fund its operations; and other risks and uncertainties described herein, as well as those risks and uncertainties discussed from time to time in other reports and other public filings with the SEC by Revelation.

REVELATION BIOSCIENCES, INC. Condensed Consolidated Statements of Operations (Unaudited)
		Three Months Ended September 30,								Nine Months Ended September 30,
		2022				2021				2022				2021
Operating expenses:
Research and development		$	381,566			$	1,532,782			$	5,037,429			$	4,249,326
General and administrative			817,898				1,511,165				4,608,755				3,844,212
Total operating expenses			1,199,464				3,043,947				9,646,184				8,093,538
Loss from operations			(1,199,464	)			(3,043,947	)			(9,646,184	)			(8,093,538	)
Other income (expense):
Other income (expense)			28,728				(557	)			24,221				(32,913	)
Total other income (expense), net			28,728				(557	)			24,221				(32,913	)
Net loss		$	(1,170,736	)		$	(3,044,504	)		$	(9,621,963	)		$	(8,126,451	)
Net loss per share, basic and diluted		$	(0.06	)		$	(0.48	)		$	(0.57	)		$	(3.83	)
Weighted-average shares used to compute net loss per share, basic and diluted			21,055,211				6,291,690				16,805,082				2,120,276

REVELATION BIOSCIENCES, INC. Condensed Consolidated Balance Sheets (Unaudited)
		September 30, 2022				December 31, 2021
ASSETS
Current assets:
Cash and cash equivalents		$	6,195,446			$	1,274,729
Prepaid expenses and other current assets			309,628				637,342
Total current assets			6,505,074				1,912,071
Property and equipment, net			96,395				115,181
Right-of-use lease asset			—				14,960
Total assets		$	6,601,469			$	2,042,212
LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT)
Current liabilities:
Accounts payable		$	466,084			$	596,261
Accrued expenses			996,447				1,528,669
Lease liability			—				16,752
Deferred underwriting commissions			2,911,260				—
Total current liabilities			4,373,791				2,141,682
Total liabilities			4,373,791				2,141,682
Commitments and Contingencies
Stockholders’ equity (deficit):
Series A Preferred Stock, $0.001 par value; zero and 628,930 shares authorized, issued and outstanding at September 30, 2022 and December 31, 2021, respectively; liquidation preference of $0 and $3,999,995 at September 30, 2022 and December 31, 2021, respectively			—				3,903,730
Series A-1 Preferred Stock, $0.001 par value; zero and 1,100,000 shares authorized and zero and 684,450 shares issued and outstanding at September 30, 2022 and December 31, 2021, respectively; liquidation preference of $0 and $4,353,102 at September 30, 2022 and December 31, 2021, respectively			—				3,578,197
Common Stock, $0.001 par value; 100,000,000 and 11,000,000 shares authorized and 23,536,070 and 2,308,877 issued and outstanding at September 30, 2022 and December 31, 2021, respectively			23,536				2,309
Additional paid-in-capital			26,343,404				6,933,593
Accumulated deficit			(24,139,262	)			(14,517,299	)
Total stockholders’ equity (deficit)			2,227,678				(99,470	)
Total liabilities and stockholders’ equity (deficit)		$	6,601,469			$	2,042,212

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20221110006125/en/

Company Contacts

Sandra Vedrick

Vice President, Investor Relations & Human Resources

Revelation Biosciences Inc.

Email: svedrick@revbiosciences.com

and

Chester Zygmont, III

Chief Financial Officer

Revelation Biosciences Inc.

Email: czygmont@revbiosciences.com

Source: Revelation Biosciences Inc.

FAQ

What are Revelation Biosciences' recent financial results for Q3 2022?

Revelation reported a net loss of $1.2 million, improved from $3.0 million in Q3 2021.

How much cash does Revelation Biosciences have as of September 30, 2022?

The company has $6.2 million in cash and cash equivalents.

What is the significance of the $5 million public offering completed by REVB?

The offering enhances the company's liquidity to fund ongoing operations and clinical studies.

What clinical advancements did Revelation Biosciences announce recently?

The company highlighted positive data for REVTx-300 in kidney injury, and confirmed initiation of clinical studies for REVTx-100 and REVTx-300.